Taisho Signs Agreement With Mochida On Epadel Switch OTC’s Marketing Rights
This article was originally published in PharmAsia News
Executive Summary
Japanese major over-the-counter drug maker Taisho Pharmaceutical signed an agreement with Mochida Pharmaceutical and obtained exclusive marketing rights to hyperlipidemia drug Epadel (ethyl icosapentate) switch OTC products. Mochida is the world's first drug maker to develop high grade ethyl icosapentate as a therapeutic agent to treat symptoms of hyperlipidemia and arteriosclerosis obliterans. Epadel was launched in Japan in 1990 and Mochida is applying for manufacturing and marketing approval for the drug's switch to OTC products. Taisho has a broad sales network and extensive marketing experience in Japan's OTC market. (Click here for more - Japanese language